Disease · HP_0001662
Bradycardia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Bradycardia. Diseases, record HP_0001662. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001662
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Bradycardia
- Open Targets ID
- HP_0001662
- Other names
- Brachycardia, Slow heartbeats
- Highest stage of its drugs
- Phase 3, for 6 of its 20 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs20
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ATROPINE | CHEMBL517712 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DIPHTHERIA TOXOID | CHEMBL2109121 | Vaccine component | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| DOXAPRAM | CHEMBL1754 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| REMIFENTANIL | CHEMBL1005 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 | CHEMBL6068493 | Vaccine component | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CAFFEINE CITRATE | CHEMBL1200569 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IBUPROFEN | CHEMBL521 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NOREPINEPHRINE | CHEMBL1437 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ONDANSETRON | CHEMBL46 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 20
See all 20 drugsTargets43
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRA2A | Adrenergic receptor | 4 | Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist | Phase 2 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor | 4 | Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist | Phase 2 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor | 4 | Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist | Phase 2 | https://conductscience.org/library/genes/152 | Drugs and targets |
| ADRA1A | Adrenergic receptor | 3 | Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist | Phase 2 | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor | 3 | Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist | Phase 2 | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor | 3 | Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist | Phase 2 | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRB1 | Adrenergic receptor | 2 | Adrenergic receptor agonist | Phase 2 | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor | 2 | Adrenergic receptor agonist | Phase 2 | https://conductscience.org/library/genes/154 | Drugs and targets |
| ADRB3 | Adrenergic receptor | 2 | Adrenergic receptor agonist | Phase 2 | https://conductscience.org/library/genes/155 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Unknown | https://conductscience.org/library/genes/2554 | Drugs and targets |
1 to 10 of 43
See all 43 targetsTrials14
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01841606 | The Effect of Ondansetron on Cardiac Output in Elective Cesarean Deliveries | Phase 2 | 57 | 2018-05-11 | Cardiac Output | ONDANSETRON | Its record names the disease | ClinicalTrials.gov |
| NCT02726178 | Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants | Phase 2 | 56 | 2017-06-05 | Complication Due to Immunization | IBUPROFEN | Its record names the disease | ClinicalTrials.gov |
| NCT04430790 | Doxapram Therapy in Preterm Infants (DOXA Trial) | Phase 3 | 396 | Apnea of Prematurity, Respiratory Insufficiency | DOXAPRAM | Its record names the disease | ClinicalTrials.gov | |
| NCT05383534 | To Study the Pharmacokinetic and Cardiovascular Effects of Propofol With Respect to Pharmacogenetics in Pakistani Population | 250 | Healthy Volunteer | PROPOFOL | Its record names the disease | ClinicalTrials.gov | ||
| NCT03477994 | Efficacy of Dexmedetomidine Versus Clonidine to Control Delirium in Patients Undergoing CABG | Not applicable | 147 | Delirium on Emergence | CLONIDINE, DEXMEDETOMIDINE | Its record names the disease | ClinicalTrials.gov | |
| NCT07363941 | HEIGHT-BASED AND CONVENTIONAL SPINAL ANAESTHETIC DOSING IN GERIATRIC PATIENTS | Not applicable | 104 | Geriatric Population, Spinal Anesthesia Induced Hypotension, Spinal Anesthesia in Elderly Patients | BUPIVACAINE, DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov | |
| NCT02732197 | Effects of Sedation on Spinal Anesthesia-induced Maternal Hypotension | 102 | Cesarean Section, Preoperative Anxiety, Spinal Anesthesia, Sedation, Maternal Hypotension | THIOPENTAL | Its record names the disease | ClinicalTrials.gov | ||
| NCT03702400 | Norepinephrine or Phenylephrine in Bolus for Hypotension in Cesarean Delivery | Phase 2 | 72 | Hypotension, Spinal Anesthesia | NOREPINEPHRINE, PHENYLEPHRINE | Its record names the disease | ClinicalTrials.gov | |
| NCT05658380 | Impact of Pre-spinal Atropine on Post Spinal Hemodynamics and Cardiac Output Measured by Electrical Cardiometry in Caesarean Delivery | Phase 3 | 60 | Anesthesia | ATROPINE, SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01857141 | Comparative Study on the Effects of Epidural Dexmedetomidine on Heart Rate Variability During General Anesthesia in Patients Undergoing Gastrectomy | Not applicable | 38 | Gastric Cancer | DEXMEDETOMIDINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 14
See all 14 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Advil® Pediatric Drops for Infants vs Control: serious adverse events | 0 of 28 | 0 of 28 | 56 | NCT02726178 | Trial comparisons |
| Ondansetron vs Placebo: serious adverse events | 0 of 25 | 0 of 27 | 52 | NCT01841606 | Trial comparisons |
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001662
GET https://conductscience.org/api/diseases/v1/HP_0001662/targets?page=2